Today (January 5), 3D Pharmaceuticals (3D Pharmaceuticals) announced a cooperation agreement with Y-Biologics, a South Korean biotech company, to obtain exclusive development, production and commercial rights for the latter's dual-specific antibody YBL-013 in Greater China, and will jointly develop the product worldwide.
YBL-013 is a new dual-specific antibody drug based on Y-Biologics' unique Antipodean Like Cell Engager (ALiCE) platform that can act on both CD3 subjects of T cells and PD-L1 of tumor cells.
it is known that the technology is genetically engineered on the traditional antibody structure to have a unique 2:1 structure, including two targeted tumor antigen Fab region and a specific target T cell cd3 receptor Fv region, specifically activated tumor exosome T cells.
this technique, can greatly reduce the current T-cell dual-specific antibodies may have toxic side effects.
Under the terms of the agreement, Y-Biologics will be responsible for the development costs of the YBL-013 portion of IND and will receive a $2 million contract and be eligible for additional development, registration, commercialization and sales milestone payments of up to $85 million, as well as licensing fees of up to double-digit net sales in the authorized region.
YBL-013 will receive exclusive development, production and commercial rights in Greater China, as well as joint development or priority rights for YBL-013 in other regions of the world.